betadex and Heart-Failure

Topics: A549 Cells; Administration, Inhalation; Animals; Anti-Inflammatory Agents; beta-Cyclodextrins; Cardiomyopathies; Cell Line; Doxorubicin; Drug Delivery Systems; Heart; Heart Failure; Humans; Inflammation; Lung; Mice; Nanoparticles; Primary Cell Culture; Pulmonary Circulation; Rats; Rats, Sprague-Dawley; RAW 264.7 Cells; Reactive Oxygen Species; Theranostic Nanomedicine

To compare the effects of angiotensin converting enzyme inhibition (ACEI) (captopril 1 mg/kg i.v.) to direct renin inhibition (CP80794 3 mg/kg i.v.) on left ventricular and systemic hemodynamics and peripheral blood flows in advanced congestive heart failure (CHF).. Conscious chronically instrumented dogs (n = 14) were treated with captopril, 1 mg/kg, i.v., or CP80794, 3 mg/kg, i.v., before and after development of advanced CHF induced by 4-7 weeks of rapid ventricular pacing. After advanced CHF, comparisons between the inhibitors were made at equihypotensive doses.. In advanced CHF, both agents caused comparable reductions in mean arterial pressure (MAP) (-22% from 79 +/- 4 mmHg) and comparable increases (P < 0.01) in cardiac output (CP80794, 1.4 +/- 0.3 to 1.8 +/- 0.1 l/min; captopril, 1.4 +/- 0.1 to 1.9 +/- 0.1 l/min). Neither agent had a significant effect on LV contractility. In contrast, CP80794 caused a greater (P < 0.05) increase in renal blood flow (66 +/- 6% from 64 +/- 5 ml/min) compared to captopril (33 +/- 4% from 66 +/- 7 ml/min).. Renin inhibition with CP80794 and ACEI with captopril caused comparable hemodynamic effects in advanced CHF. However, CP80794 caused significantly greater increases in renal blood flow and suppressed renin activity to a greater degree than captopril.

Topics: 2-Hydroxypropyl-beta-cyclodextrin; Angiotensin-Converting Enzyme Inhibitors; Animals; beta-Cyclodextrins; Blood Pressure; Captopril; Cardiac Pacing, Artificial; Cyclodextrins; Dipeptides; Dogs; Dose-Response Relationship, Drug; Female; Heart Failure; Male; Morpholines; Regional Blood Flow; Renal Circulation; Renin